 <h1>Oravig Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>miconazole</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about miconazole. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Oravig.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to miconazole: buccal mucosa tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, miconazole (the active ingredient contained in Oravig) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking miconazole:</p><p>
<i>Less common</i>
</p><ul>
<li>Body aches or pain</li>
<li>cough</li>
<li>difficulty with breathing</li>
<li>ear congestion</li>
<li>fever or chills</li>
<li>headache</li>
<li>loss of voice</li>
<li>lower back or side pain</li>
<li>nasal congestion</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>runny nose</li>
<li>sneezing</li>
<li>sore throat</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Black, tarry stools</li>
<li>pale skin</li>
<li>shortness of breath</li>
<li>ulcers, sores, or white spots in the mouth</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of miconazole may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Change in taste</li>
<li>diarrhea</li>
<li>dry mouth</li>
<li>headache</li>
<li>itching skin</li>
<li>loss of taste</li>
<li>nausea</li>
<li>pain, redness, and swelling of the gums</li>
<li>sores on the tongue</li>
<li>toothache</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>loss of appetite</li>
<li>pain</li>
<li>upper abdominal or stomach pain</li>
<li>weakness</li>
</ul><p>
<!-- end buccal mucosa tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to miconazole: buccal tablet, intravenous solution</i></p><h3>General</h3><p>The overall safety of the buccal tablets was assessed in 480 adult subjects, including 315 HIV-infected subjects, 147 subjects with head and neck cancer, and 18 healthy subjects.  Discontinuation due to side effects occurred in 0.6% of subjects overall.</p>
<p></p>
<p>The most common side effects reported with the oral gel were nausea, abnormal product taste, vomiting, oral discomfort, regurgitation, dry mouth, and dysgeusia.</p>
<p></p>
<p>Although the IV product has been discontinued in the US, side effects associated with this formulation have been included.<sup>[Ref]</sup></p><h3>Local</h3><p>Local side effects (including oral discomfort, oral burning, oral pain, gingival pain, gingival swelling, gingival pruritus, tongue ulceration, mouth ulceration, glossodynia, dry mouth, application site pain/discomfort, toothache, loss of taste, altered taste) have been reported in 12.1% of HIV-infected patients.  Local side effects (including oral discomfort, oral pain, dry mouth, glossodynia, loss of taste, altered taste, tongue ulceration, mouth ulceration, tooth disorder, application site discomfort/pain) have been reported in 9.5% of patients with head and neck cancer.<sup>[Ref]</sup></p><p>Buccal tablets:</p>
<p>-Very common (10% or more): Local side effects (including oral discomfort, oral burning, oral pain, gingival pain, gingival swelling, gingival pruritus, tongue ulceration, mouth ulceration, glossodynia, dry mouth, application site pain/discomfort, toothache, loss of taste, altered taste, tooth disorder)</p>
<p></p>
<p>IV formulation:</p>
<p>-Very common (10% or more): Phlebitis (at least 33%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Buccal tablets:</p>
<p>-Common (1% to 10%): Diarrhea, nausea, vomiting, dry mouth, oral discomfort, upper abdominal pain, gastroenteritis</p>
<p></p>
<p>Oral gel:</p>
<p>-Common (1% to 10%): Dry mouth, nausea, oral discomfort, vomiting, regurgitation</p>
<p>-Postmarketing reports: Diarrhea, stomatitis, tongue discoloration</p>
<p></p>
<p>IV formulation:</p>
<p>-Frequency not reported: Nausea, vomiting, anorexia, diarrhea<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Buccal tablets:</p>
<p>-Common (1% to 10%): Headache, dysgeusia, ageusia</p>
<p></p>
<p>Oral gel:</p>
<p>-Common (1% to 10%): Dysgeusia</p>
<p></p>
<p>IV formulation:</p>
<p>-Frequency not reported: Dizziness<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Buccal tablets:</p>
<p>-Common (1% to 10%): Cough, upper respiratory infection, pharyngeal pain</p>
<p></p>
<p>Oral gel:</p>
<p>-Postmarketing reports: Choking<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Increases in INR and bleeding events (e.g., epistaxis, contusion, hematuria, melena, hematemesis, hematoma, hemorrhages) have been reported in patients treated with oral anticoagulants (e.g., warfarin) and this oral gel; some events had fatal outcomes.<sup>[Ref]</sup></p><p>Buccal tablets:</p>
<p>-Common (1% to 10%): Anemia, lymphopenia</p>
<p>-Uncommon (0.1% to 1%): Neutropenia</p>
<p></p>
<p>Oral gel:</p>
<p>-Frequency not reported: Increase in INR, increase in bleeding events (e.g., epistaxis, contusion, hematuria, melena, hematemesis, hematoma, hemorrhages)</p>
<p></p>
<p>IV formulation:</p>
<p>-Frequency not reported: Transient decreases in hematocrit, thrombocytosis, thrombocytopenia, erythrocyte aggregation<sup>[Ref]</sup></p><h3>Other</h3><p>Buccal tablets:</p>
<p>-Common (1% to 10%): Fatigue, pain</p>
<p></p>
<p>Oral gel:</p>
<p>-Common (1% to 10%): Abnormal product taste</p>
<p>-Postmarketing reports: Malaise, chills</p>
<p></p>
<p>IV formulation:</p>
<p>-Frequency not reported: Fever, chills<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Pruritus (which may have been accompanied by maculopapular rash) has been reported with the IV formulation, and in some cases, severe pruritus developed after weeks of therapy or after therapy was completed.<sup>[Ref]</sup></p><p>Buccal tablets:</p>
<p>-Common (1% to 10%): Pruritus</p>
<p></p>
<p>Oral gel:</p>
<p>-Postmarketing reports: Angioedema, toxic epidermal necrolysis (Lyell syndrome), Stevens-Johnson syndrome, urticaria, rash, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms</p>
<p></p>
<p>IV formulation:</p>
<p>-Frequency not reported: Pruritus, maculopapular rash<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Buccal tablets:</p>
<p>-Common (1% to 10%): Elevated GGT</p>
<p></p>
<p>Oral gel:</p>
<p>-Postmarketing reports: Hepatitis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Contact dermatitis has been reported when the IV formulation was used topically.<sup>[Ref]</sup></p><p>Buccal tablets:</p>
<p>-Frequency not reported: Allergic reaction (including anaphylactic reactions, hypersensitivity)</p>
<p></p>
<p>Oral gel:</p>
<p>-Postmarketing reports: Allergic conditions (including angioneurotic edema, anaphylactic reaction), hypersensitivity</p>
<p></p>
<p>IV formulation:</p>
<p>-Frequency not reported: Anaphylaxis, contact dermatitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Increases in cholesterol and triglycerides reported in patients receiving the IV formulation were due to its vehicle (Cremophor EL [polyethoxylated castor oil]), and were reversible upon discontinuation of the drug.  Hyperlipidemia due to Cremophor EL had the atypical appearance of gamma-2 globulin.</p>
<p></p>
<p>Hyponatremia associated with the IV formulation resulted in a mean decrease in sodium of 10 mEq/L, but usually was not a reason to discontinue therapy.  This drug was usually administered in normal saline solution to help minimize decreases in sodium.<sup>[Ref]</sup></p><p>Oral gel:</p>
<p>-Postmarketing reports: Anorexia</p>
<p></p>
<p>IV formulation:</p>
<p>-Frequency not reported: Hyperlipidemia, hyponatremia<sup>[Ref]</sup></p><h3>Ocular</h3><p>Oral gel:</p>
<p>-Postmarketing reports: Accommodation difficulty</p>
<p></p>
<p>IV formulation:</p>
<p>-Frequency not reported: Blurred vision</p><h3>Cardiovascular</h3><p>IV formulation:</p>
<p>-Frequency not reported: Cardiac arrhythmias, tachycardia, cardiac arrest<sup>[Ref]</sup></p><p>Cardiac arrhythmias, tachycardia, and cardiac arrest may have been associated with rapid infusion of the drug and due to the Cremophor EL vehicle.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>IV formulation:</p>
<p>-Frequency not reported: Euphoria</p><h3>Renal</h3><p>Acute renal failure, possibly due to the IV formulation, was reported in 1 patient with a renal allograft.<sup>[Ref]</sup></p><p>IV formulation:</p>
<p>-Frequency not reported: Acute renal failure<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Stevens D "Miconazole in the treatment of systemic fungal infections." Am Rev Respir Dis 116 (1977): 801-6</p><p id="ref_2">2. "Product Information. ORAVIG (miconazole)." Strativa  Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_5">5. Fischer TJ, Klein RB, Kershnar HE, Borut TC, Stiehm ER "Miconazole in the treatment of chronic mucocutaneous candidiasis: a preliminary report." J Pediatr 91 (1977): 815-9</p><p id="ref_6">6. Bodey GP "Topical and systemic antifungal agents." Med Clin North Am 72 (1988): 637-59</p><p id="ref_7">7. Wade TR, Jones HE, Chanda JJ "Intravenous miconazole therapy of mycotic infections." Arch Intern Med 139 (1979): 784-6</p><p id="ref_8">8. Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS "Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections." Drugs 19 (1980): 7-30</p><p id="ref_9">9. "Product Information. Monistat (miconazole)." Ortho Pharmaceutical Corporation, Raritan, NJ. </p><p id="ref_10">10. Marmion LC, Desser KB, Lilly RB, Stevens DA "Reversible thrombocytosis and anemia due to miconazole therapy." Antimicrob Agents Chemother 10 (1976): 447-9</p><p id="ref_11">11. Degreef H, Verhoeve L "Contact dermatitis to miconazole nitrate." Contact Dermatitis 1 (1975): 269-70</p><p id="ref_12">12. Barr RJ, Fujita WH, Graham JH "Eruptive xanthomas associated with intravenous miconazole therapy." Arch Dermatol 114 (1978): 1544-5</p><p id="ref_13">13. Fernandez L, Maquiera E, Rodriguez F, Picans I, Duque S "Systemic contact dermatitis from miconazole." Contact Dermatitis 34 (1996): 217</p><p id="ref_14">14. Fainstein V, Bodey GP "Cardiorespiratory toxicity due to miconazole." Ann Intern Med 93 (1980): 432-3</p><p id="ref_15">15. Baes H "Contact sensitivity to miconazole with ortho-chloro cross-sensitivity to other imidazoles." Contact Dermatitis 24 (1991): 89-93</p><p id="ref_16">16. Wade TR, Jones HE, Artis WA "Irritant and allergic reactions to topically applied Micatin cream." Contact Dermatitis 5 (1979): 168-70</p><p id="ref_17">17. Raulin C, Frosch PJ "Contact allergy to imidazole antimycotics." Contact Dermatitis 18 (1988): 76-80</p><p id="ref_18">18. Perret CM, Happle R "Contact allergy to miconazole." Contact Dermatitis 19 (1988): 75</p><p id="ref_19">19. Rose HD, Roth DA, Barboriak JJ "Hyperlipidemia related to miconazole therapy." Ann Intern Med 91 (1979): 491-2</p><p id="ref_20">20. Bagnarello AG, Lewis LA, McHenry MC, Weinstein AJ, Naito HK, McCullough AJ, Lederman RJ, Gavan TL "Unusual serum lipoprotein abnormality induced by the vehicle of miconazole." N Engl J Med 296 (1977): 497-9</p><p id="ref_21">21. Naito HK, McHenry MC, Lewis LA "Drug-induced dyslipoproteinemia: a report of two cases." Clin Chem 26 (1980): 163-8</p><p id="ref_22">22. Coley KC, Crain JL "Miconazole-induced fatal dysrhythmia." Pharmacotherapy 17 (1997): 379-82</p><p id="ref_23">23. Lai KN, Newton M, Seymour A, Pugsley D, Jones T "Miconazole treatment after renal transplantation." Lancet 4 (1981): 48-9</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Oravig (miconazole)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: azole antifungals</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Oravig &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Oral Thrush</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to miconazole: buccal tablet, intravenous solution</i></p><h3>General</h3><p>The overall safety of the buccal tablets was assessed in 480 adult subjects, including 315 HIV-infected subjects, 147 subjects with head and neck cancer, and 18 healthy subjects.  Discontinuation due to side effects occurred in 0.6% of subjects overall.</p><p></p><p>The most common side effects reported with the oral gel were nausea, abnormal product taste, vomiting, oral discomfort, regurgitation, dry mouth, and dysgeusia.</p><p></p><p>Although the IV product has been discontinued in the US, side effects associated with this formulation have been included.<sup>[Ref]</sup></p><h3>Local</h3><p>Local side effects (including oral discomfort, oral burning, oral pain, gingival pain, gingival swelling, gingival pruritus, tongue ulceration, mouth ulceration, glossodynia, dry mouth, application site pain/discomfort, toothache, loss of taste, altered taste) have been reported in 12.1% of HIV-infected patients.  Local side effects (including oral discomfort, oral pain, dry mouth, glossodynia, loss of taste, altered taste, tongue ulceration, mouth ulceration, tooth disorder, application site discomfort/pain) have been reported in 9.5% of patients with head and neck cancer.<sup>[Ref]</sup></p><p>Buccal tablets:</p><p>-Very common (10% or more): Local side effects (including oral discomfort, oral burning, oral pain, gingival pain, gingival swelling, gingival pruritus, tongue ulceration, mouth ulceration, glossodynia, dry mouth, application site pain/discomfort, toothache, loss of taste, altered taste, tooth disorder)</p><p></p><p>IV formulation:</p><p>-Very common (10% or more): Phlebitis (at least 33%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Buccal tablets:</p><p>-Common (1% to 10%): Diarrhea, nausea, vomiting, dry mouth, oral discomfort, upper abdominal pain, gastroenteritis</p><p></p><p>Oral gel:</p><p>-Common (1% to 10%): Dry mouth, nausea, oral discomfort, vomiting, regurgitation</p><p>-Postmarketing reports: Diarrhea, stomatitis, tongue discoloration</p><p></p><p>IV formulation:</p><p>-Frequency not reported: Nausea, vomiting, anorexia, diarrhea<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Buccal tablets:</p><p>-Common (1% to 10%): Headache, dysgeusia, ageusia</p><p></p><p>Oral gel:</p><p>-Common (1% to 10%): Dysgeusia</p><p></p><p>IV formulation:</p><p>-Frequency not reported: Dizziness<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Buccal tablets:</p><p>-Common (1% to 10%): Cough, upper respiratory infection, pharyngeal pain</p><p></p><p>Oral gel:</p><p>-Postmarketing reports: Choking<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Increases in INR and bleeding events (e.g., epistaxis, contusion, hematuria, melena, hematemesis, hematoma, hemorrhages) have been reported in patients treated with oral anticoagulants (e.g., warfarin) and this oral gel; some events had fatal outcomes.<sup>[Ref]</sup></p><p>Buccal tablets:</p><p>-Common (1% to 10%): Anemia, lymphopenia</p><p>-Uncommon (0.1% to 1%): Neutropenia</p><p></p><p>Oral gel:</p><p>-Frequency not reported: Increase in INR, increase in bleeding events (e.g., epistaxis, contusion, hematuria, melena, hematemesis, hematoma, hemorrhages)</p><p></p><p>IV formulation:</p><p>-Frequency not reported: Transient decreases in hematocrit, thrombocytosis, thrombocytopenia, erythrocyte aggregation<sup>[Ref]</sup></p><h3>Other</h3><p>Buccal tablets:</p><p>-Common (1% to 10%): Fatigue, pain</p><p></p><p>Oral gel:</p><p>-Common (1% to 10%): Abnormal product taste</p><p>-Postmarketing reports: Malaise, chills</p><p></p><p>IV formulation:</p><p>-Frequency not reported: Fever, chills<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Pruritus (which may have been accompanied by maculopapular rash) has been reported with the IV formulation, and in some cases, severe pruritus developed after weeks of therapy or after therapy was completed.<sup>[Ref]</sup></p><p>Buccal tablets:</p><p>-Common (1% to 10%): Pruritus</p><p></p><p>Oral gel:</p><p>-Postmarketing reports: Angioedema, toxic epidermal necrolysis (Lyell syndrome), Stevens-Johnson syndrome, urticaria, rash, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms</p><p></p><p>IV formulation:</p><p>-Frequency not reported: Pruritus, maculopapular rash<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Buccal tablets:</p><p>-Common (1% to 10%): Elevated GGT</p><p></p><p>Oral gel:</p><p>-Postmarketing reports: Hepatitis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Contact dermatitis has been reported when the IV formulation was used topically.<sup>[Ref]</sup></p><p>Buccal tablets:</p><p>-Frequency not reported: Allergic reaction (including anaphylactic reactions, hypersensitivity)</p><p></p><p>Oral gel:</p><p>-Postmarketing reports: Allergic conditions (including angioneurotic edema, anaphylactic reaction), hypersensitivity</p><p></p><p>IV formulation:</p><p>-Frequency not reported: Anaphylaxis, contact dermatitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Increases in cholesterol and triglycerides reported in patients receiving the IV formulation were due to its vehicle (Cremophor EL [polyethoxylated castor oil]), and were reversible upon discontinuation of the drug.  Hyperlipidemia due to Cremophor EL had the atypical appearance of gamma-2 globulin.</p><p></p><p>Hyponatremia associated with the IV formulation resulted in a mean decrease in sodium of 10 mEq/L, but usually was not a reason to discontinue therapy.  This drug was usually administered in normal saline solution to help minimize decreases in sodium.<sup>[Ref]</sup></p><p>Oral gel:</p><p>-Postmarketing reports: Anorexia</p><p></p><p>IV formulation:</p><p>-Frequency not reported: Hyperlipidemia, hyponatremia<sup>[Ref]</sup></p><h3>Ocular</h3><p>Oral gel:</p><p>-Postmarketing reports: Accommodation difficulty</p><p></p><p>IV formulation:</p><p>-Frequency not reported: Blurred vision</p><h3>Cardiovascular</h3><p>IV formulation:</p><p>-Frequency not reported: Cardiac arrhythmias, tachycardia, cardiac arrest<sup>[Ref]</sup></p><p>Cardiac arrhythmias, tachycardia, and cardiac arrest may have been associated with rapid infusion of the drug and due to the Cremophor EL vehicle.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>IV formulation:</p><p>-Frequency not reported: Euphoria</p><h3>Renal</h3><p>Acute renal failure, possibly due to the IV formulation, was reported in 1 patient with a renal allograft.<sup>[Ref]</sup></p><p>IV formulation:</p><p>-Frequency not reported: Acute renal failure<sup>[Ref]</sup></p><p id="ref_1">1. Stevens D "Miconazole in the treatment of systemic fungal infections." Am Rev Respir Dis 116 (1977): 801-6</p><p id="ref_2">2. "Product Information. ORAVIG (miconazole)." Strativa  Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ. </p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_4">4. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_5">5. Fischer TJ, Klein RB, Kershnar HE, Borut TC, Stiehm ER "Miconazole in the treatment of chronic mucocutaneous candidiasis: a preliminary report." J Pediatr 91 (1977): 815-9</p><p id="ref_6">6. Bodey GP "Topical and systemic antifungal agents." Med Clin North Am 72 (1988): 637-59</p><p id="ref_7">7. Wade TR, Jones HE, Chanda JJ "Intravenous miconazole therapy of mycotic infections." Arch Intern Med 139 (1979): 784-6</p><p id="ref_8">8. Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS "Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections." Drugs 19 (1980): 7-30</p><p id="ref_9">9. "Product Information. Monistat (miconazole)." Ortho Pharmaceutical Corporation, Raritan, NJ. </p><p id="ref_10">10. Marmion LC, Desser KB, Lilly RB, Stevens DA "Reversible thrombocytosis and anemia due to miconazole therapy." Antimicrob Agents Chemother 10 (1976): 447-9</p><p id="ref_11">11. Degreef H, Verhoeve L "Contact dermatitis to miconazole nitrate." Contact Dermatitis 1 (1975): 269-70</p><p id="ref_12">12. Barr RJ, Fujita WH, Graham JH "Eruptive xanthomas associated with intravenous miconazole therapy." Arch Dermatol 114 (1978): 1544-5</p><p id="ref_13">13. Fernandez L, Maquiera E, Rodriguez F, Picans I, Duque S "Systemic contact dermatitis from miconazole." Contact Dermatitis 34 (1996): 217</p><p id="ref_14">14. Fainstein V, Bodey GP "Cardiorespiratory toxicity due to miconazole." Ann Intern Med 93 (1980): 432-3</p><p id="ref_15">15. Baes H "Contact sensitivity to miconazole with ortho-chloro cross-sensitivity to other imidazoles." Contact Dermatitis 24 (1991): 89-93</p><p id="ref_16">16. Wade TR, Jones HE, Artis WA "Irritant and allergic reactions to topically applied Micatin cream." Contact Dermatitis 5 (1979): 168-70</p><p id="ref_17">17. Raulin C, Frosch PJ "Contact allergy to imidazole antimycotics." Contact Dermatitis 18 (1988): 76-80</p><p id="ref_18">18. Perret CM, Happle R "Contact allergy to miconazole." Contact Dermatitis 19 (1988): 75</p><p id="ref_19">19. Rose HD, Roth DA, Barboriak JJ "Hyperlipidemia related to miconazole therapy." Ann Intern Med 91 (1979): 491-2</p><p id="ref_20">20. Bagnarello AG, Lewis LA, McHenry MC, Weinstein AJ, Naito HK, McCullough AJ, Lederman RJ, Gavan TL "Unusual serum lipoprotein abnormality induced by the vehicle of miconazole." N Engl J Med 296 (1977): 497-9</p><p id="ref_21">21. Naito HK, McHenry MC, Lewis LA "Drug-induced dyslipoproteinemia: a report of two cases." Clin Chem 26 (1980): 163-8</p><p id="ref_22">22. Coley KC, Crain JL "Miconazole-induced fatal dysrhythmia." Pharmacotherapy 17 (1997): 379-82</p><p id="ref_23">23. Lai KN, Newton M, Seymour A, Pugsley D, Jones T "Miconazole treatment after renal transplantation." Lancet 4 (1981): 48-9</p><h2>More about Oravig (miconazole)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: azole antifungals</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Oravig &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Oral Thrush</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>